His work on Internal medicine as part of his general Toxicity study is frequently connected to Gastroenterology, thereby bridging the divide between different branches of science. His Internal medicine study frequently links to other fields, such as Toxicity. Filippo de Braud undertakes multidisciplinary studies into Gastroenterology and Oncology in his work. He integrates many fields, such as Oncology and Cancer research, in his works. By researching both Cancer research and Colorectal cancer, he produces research that crosses academic boundaries. Filippo de Braud merges Cancer with Regimen in his research. He merges many fields, such as Regimen and Chemotherapy, in his writings. Filippo de Braud undertakes multidisciplinary investigations into Chemotherapy and Neutropenia in his work. Many of his studies on Surgery apply to Randomized controlled trial as well.
Filippo de Braud has begun a study into Cancer, looking into Colorectal cancer and Breast cancer. Filippo de Braud performs integrative study on Colorectal cancer and Chemotherapy. He connects Chemotherapy with Cisplatin in his research. He combines topics linked to Phases of clinical research with his work on Internal medicine. Filippo de Braud integrates many fields, such as Oncology and Cancer research, in his works. In his works, he undertakes multidisciplinary study on Cancer research and Oncology. Many of his studies on Surgery apply to Regimen as well. His Regimen study frequently involves adjacent topics like Surgery. In his research, he performs multidisciplinary study on Gastroenterology and Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont;A. Figer;M. Seymour;M. Homerin.
Journal of Clinical Oncology (2000)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer;Igor Bondarenko;Anatoly Makhson;Joerg T. Hartmann.
Journal of Clinical Oncology (2009)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko.
The New England Journal of Medicine (2014)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko.
The Lancet (2015)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott.
Lancet Oncology (2016)
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C. Bokemeyer;I. Bondarenko;J. T. Hartmann;F. de Braud.
Annals of Oncology (2011)
Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
Daniel G. Haller;Josep Tabernero;Jean Maroun;Filippo De Braud.
Journal of Clinical Oncology (2011)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel.
Cancer Discovery (2017)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Padmanee Sharma;Margaret K. Callahan;Petri Bono;Joseph Kim.
Lancet Oncology (2016)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao;Timothy M Pawlik;Robert A Anders;Florin M Selaru.
Nature Genetics (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: